Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Chemours Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Chemours Co's regulatory disclosures and financial reporting.
On 08/01/2025, Chemours (CC) President & CEO Denise Dignam filed a Form 4 disclosing an automatic share withholding (Transaction Code F) tied to vested restricted stock units.
- Shares withheld: 466 common shares at $11.50, executed solely to satisfy tax obligations; no open-market sale occurred and the trade is Rule 16b-3 exempt.
- Remaining ownership: 187,478.1549 shares held directly, meaning the transaction reduced her stake by roughly 0.25%.
- Insider role: Dignam serves as both President & CEO and Director, maintaining substantial equity alignment with investors.
The event is routine, immaterial to Chemours’ capital structure and does not signal a change in insider sentiment.
Chemours Company (CC) Form 4 filing – 8/1/2025
President, Thermal & Specialized Solutions, Joseph T. Martinko reported an automatic share disposition coded “F,” indicating 649 common shares were withheld by the company at $11.50 to cover taxes triggered by the vesting of restricted stock units (RSUs) and related dividend-equivalent units. No shares were sold on the open market; therefore, the transaction is exempt under Rule 16b-3.
- Post-transaction beneficial ownership: 30,936.6241 shares (direct)
- Insider role: Executive officer – President, Thermal & Specialized Solutions
- Purpose: Tax withholding; routine administrative event
Given the small share count (<0.1% of total ownership) and non-cash nature, the filing is considered operationally routine with minimal investment impact.
Chemours (CC) posted a sharp swing to loss in Q2-25. Net sales rose 3.9% YoY to $1.615 billion, but gross profit contracted 9.7% to $278 million and SG&A ballooned to $437 million (vs. $154 million), driving a GAAP net loss of $380 million (-$2.54 per diluted share) versus $60 million profit a year ago. Six-month sales improved 2.3% to $2.983 billion, yet the company recorded a H1-25 loss of $384 million (-$2.56 per share) against $113 million income in H1-24.
Cash from operations was a modest -$19 million, far better than the -$910 million outflow reported in the prior-year period, helped by smaller working-capital drains. Free cash flow remained negative as Chemours spent $127 million on capex. Cash and equivalents fell to $502 million from $713 million at year-end, while long-term debt inched up to $4.102 billion. Total equity shrank to $239 million, reflecting the loss and a dividend cut to $0.0875 per share (vs. $0.25 last year).
The company cites $954 million unused capacity on its revolving credit facility and believes liquidity is adequate through August 2026, but warns that adverse outcomes in PFAS and other legal/environmental matters could be material. Management revised prior-period financials for presentation errors; impacts were immaterial.
Settlement overview. On 3 Aug 2025 Chemours, DuPont and Corteva entered a proposed Judicial Consent Order with New Jersey that would resolve all state PFAS and legacy-site contamination claims. The Companies will pay an aggregate $875 million in cash to the state, spread over 25 years starting no earlier than 1 Jan 2026; the total present value, discounted at 8%, is about $500 million. Chemours will fund 50%, DuPont 35.5% and Corteva 14.5%.
Funding & security. Site-specific Remediation Funding Sources will be backed by surety bonds, and DuPont/Corteva will establish a separate Reserve Fund (71%/29%) for future remediation. A parallel Insurance Proceeds MOU lets DuPont and Corteva purchase Chemours’ rights to $150 million of potential PFAS insurance recoveries; after repayment plus a fee, further proceeds are split 50/50. Chemours expects existing escrowed cash and the assigned insurance proceeds to cover its settlement payments through at least 2030.
Next steps & impact. The deal needs public notice, comment and court approval and contains no admission of liability. It reduces legal uncertainty and staggers cash outflows, but long-term PFAS exposure, possible additional remediation costs and regulatory shifts remain key risks, as outlined in the forward-looking-statement section.